Written Question · S2W-20017 · Session 2
Whether imported blood plasma was present in any blood plasma products used by the NHS, or any other healthcare suppliers, between 1980 and…
The question
To ask the Scottish Executive whether imported blood plasma was present in any blood plasma products used by the NHS, or any other healthcare suppliers, between 1980 and 1988.
The answer
The Scottish National Blood TransfusionService (SNBTS) has confirmed that blood plasma products manufactured by them during1980-88 were not derived from imported plasma.
However, demand for blood plasmabased products, mainly Factor VIII for the treatment of haemophilia A patients,exceeded available supplies from SNBTS and some products were imported during theperiod. Responsibility for the purchase of imported products lay with localhealth boards and, consequently, the Executive does not hold this information centrally.
Blood plasma products are “PrescriptionOnly Medicines”. Authorisation for marketing/distribution of imported blood plasmaproducts within the UK was (and remains) the responsibility of the Medicines ControlAgency (now MHRA). Further information on imported plasma products authorised foruse in UK during this period may be obtained from Medicines and Healthcare ProductsRegulatory Agency.
However, demand for blood plasmabased products, mainly Factor VIII for the treatment of haemophilia A patients,exceeded available supplies from SNBTS and some products were imported during theperiod. Responsibility for the purchase of imported products lay with localhealth boards and, consequently, the Executive does not hold this information centrally.
Blood plasma products are “PrescriptionOnly Medicines”. Authorisation for marketing/distribution of imported blood plasmaproducts within the UK was (and remains) the responsibility of the Medicines ControlAgency (now MHRA). Further information on imported plasma products authorised foruse in UK during this period may be obtained from Medicines and Healthcare ProductsRegulatory Agency.
In the Official Report
1 contribution mention S2W-20017-
22 Dec 2005Blood Products
I welcome the debate and will support the motion in the name of Carolyn Leckie. I understand the Executive amendment and what the minister said in his statement, but I feel that although we have moved on in some respects—practical measures…